Pharmaceuticals News and Research

RSS

Affymax reports second-quarter net income of $17.3M against loss last year

Affymax, Inc. today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payments of $30.0 million from Takeda Pharmaceutical Company Limited for database lock of the Hematide/peginesatide Phase 3 clinical trials.

5 Aug 2010

Optimer second-quarter net loss decreases to $10.4 million

Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.

5 Aug 2010

AMRI second-quarter adjusted EPS increases to $0.06

AMRI today reported financial and operating results for the second quarter ended June 30, 2010.

5 Aug 2010

DURECT second-quarter net loss decreases to $6.3 million

DURECT Corporation announced today financial results for the three months ended June 30, 2010. Total revenues were $7.3 million for the three months ended June 30, 2010 compared to $4.9 million for the three months ended June 30, 2009. Net loss for the three months ended June 30, 2010 was $6.3 million, compared to a net loss of $7.5 million for the same period in 2009.

5 Aug 2010

FDA to crack down on devices; Big pharma places riskier bets on biologics

The Associated Press: "Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year. The Food and Drug Administration released recommendations Tuesday night designed to improve oversight of the U.S. device industry, including the government's ability to revoke approval for products that prove unsafe or ineffective" (Perrone, 8/3).

5 Aug 2010

Anthera second-quarter total operating expenses increase to $7.9 million

Anthera Pharmaceuticals, Inc., today announced financial results and business highlights for the second quarter ended June 30, 2010.

5 Aug 2010

AG Mednet receives patent for diagnostic imaging studies

AG Mednet, the world's largest diagnostic imaging network, announced today that the U.S. Patent Office had granted the company patent number 7765109, "Systems and methods for providing diagnostic imaging studies to one or more interpreters and selecting one or more of the interpreters to provide an interpretation of the images based on one or more variables." The patent broadly encompasses a number of key innovations in the field, all of which are made a reality for the first time by AG Mednet to all its users worldwide.

5 Aug 2010

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.

5 Aug 2010

Study links sea sponge genome sequence with first animals and cancer

The sponge, which was not recognized as an animal until the 19th century, is now the simplest and most ancient group of animals to have their genome sequenced. In a paper appearing in the August 5 issue of the journal Nature, a team of researchers led by Daniel Rokhsar of the University of California, Berkeley, and the Department of Energy's Joint Genome Institute (JGI), report the draft genome sequence of the sea sponge Amphimedon queenslandica and several insights the genome gives into the origins of both the first animals and cancer.

5 Aug 2010

Discovery Laboratories reports net loss of $6.3 million for second-quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and reports financial results for the second quarter ended June 30, 2010.

4 Aug 2010

Nuokang's product pipeline candidates advance through SFDA review process

China Nuokang Bio-Pharmaceutical Inc., a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that two of its product pipeline candidates recently advanced through the next respective stages of the State Food and Drug Administration review process.

4 Aug 2010

Insmed second-quarter net loss decreases to $0.4 million

Insmed Inc., a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2010.

4 Aug 2010

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical Companies, Inc. today reported results for the second quarter ended June 30, 2010.

4 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Pew Prescription Project announces support for new safety legislation

The Pew Prescription Project, joined by major consumer, physician and chemical manufacturer groups, today announced support for a new bill that would give the U.S. Food and Drug Administration much-needed authorities to better protect pharmaceutical supply chains. The organizations made the announcement in a joint letter to Congress and during an audio news conference with Senator Michael Bennet (D-CO), who will introduce this drug safety legislation.

4 Aug 2010

BioClinica second-quarter service revenues increase to $15.7 million

BioClinica, Inc., a global provider of clinical trial management services, today announced its financial results for the second quarter and six months ended June 30, 2010.

From Clario 4 Aug 2010

Patients taking memantine show improvement in cognitive function, Merz analyses shows

In September 2009, the German Institute for Quality and Efficiency in Health Care concluded that no benefit has been proven for memantine in the treatment of Alzheimer's disease. An assessment now presented of 2 previously unpublished studies and new analyses by the manufacturer Merz do not change this conclusion. However, IQWiG describes the deficits of the newly provided analyses and specifically illustrates how the analyses would have to be presented in order to be considered in a benefit assessment.

4 Aug 2010

Targacept licenses Cornerstone technology for inflammatory disorders program

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.

4 Aug 2010

IPS looks at anticipated impact of free-trade talks on India's generic drug industry

With reports that ongoing negotiations between India and the European Union are expected to end in a free-trade agreement "by the end of August," Inter Press Service examines the concerns among drug manufacturers and exporters over how the agreement might reduce growth in India's generic medicines industry.

4 Aug 2010

drugstore.com announces extension of strategic alliance with Medco Health Solutions

drugstore.com, inc., a leading online retailer of health, beauty, vision, and pharmacy products, today announced the extension through 2018 of its strategic alliance with Medco Health Solutions, Inc., one of the nation's leading healthcare companies.

4 Aug 2010